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Clostridium difficile infection in the Lao
People’s Democratic Republic: first isolation
and review of the literature
Elaine Cheong1,2* , Tamalee Roberts1, Sayaphet Rattanavong1, Thomas V. Riley3, Paul N. Newton1,4
and David A. B. Dance1,4,5

Abstract
Background: Current knowledge of the epidemiology of Clostridium difficile infection in Asia, and in particular the
Greater Mekong Subregion, is very limited. Only a few studies from Thailand and Vietnam have been reported from
the region with variable testing methods and results, and no studies from Lao People’s Democratic Republic (PDR).
Therefore we investigated the presence of C. difficile in a single centre in the Lao PDR and determined the ribotypes
present.
Method: Seventy unformed stool samples from hospital inpatients at Mahosot Hospital, Vientiane, were tested for the
presence of C. difficile using selective differential agar and confirmed by latex agglutination. C. difficile isolates were
further characterised by ribotyping and toxin gene detection.
Results: C. difficile was isolated from five of the 70 patients, and five different ribotypes were identified (014, 017, 020,
QX 107 and QX 574).
Conclusion: This is the first isolation of C. difficile from human stool samples in the Lao PDR. These results will add to
the limited amount of data on C. difficile in the region. In addition, we hope this information will alert clinicians to the
presence of C. difficile in the country and will help inform future investigations into the epidemiology and diagnosis of
C. difficile in Lao PDR.
Keywords: Clostridium Difficile, Lao PDR, Laos, Antibiotic associated diarrhoea, Ribotypes

Background
Clostridium difficile is an anaerobic, Gram-positive,
spore forming bacterium that causes antibiotic-associated
diarrhoea which can vary from mild and self-limiting to
serious manifestations including pseudomembranous
colitis [1]. C. difficile infection (CDI) is predominantly
healthcare-associated although increasing numbers of
community-acquired infections have been reported [2, 3].
Some strains of C. difficile have the ability to produce
three toxins - toxin A, toxin B and a binary cytolethal distending toxin (CDT), and only strains that can produce at
least one of these toxins cause disease [4].
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C. difficile is widely recognized as an important diarrheal
pathogen in North America and Europe. Epidemics have
occurred in both these regions, resulting in the development of guidelines on active surveillance of infection,
laboratory diagnosis, management and infection prevention and control, and a need for better antibiotic
stewardship within health care facilities, the community
and animal production facilities [5]. In contrast, limited
information on CDI is available in Asia [6]. Reports
from the region are highly variable with respect to the
prevalence, laboratory diagnostic methods and circulating ribotypes (RT). Not all countries in the region have
reported CDI, and comparisons within the region are
difficult to make [6].
Despite a number of reports of CDI in the neighbouring
countries of Thailand [7] and China [8], there have been
no published reports on the isolation of C. difficile in
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Lao People’s Democratic Republic (Lao PDR, Laos).
Cephalosporins, particularly ceftriaxone, are used extensively in hospitals in Laos, which may carry an associated
risk of CDI. We therefore investigated the prevalence of
C. difficile from stool samples from hospitalised patients
from a single centre within Laos and characterised all C.
difficile isolates.

Methods
The investigation was conducted in the Microbiology
Laboratory at Mahosot Hospital during September and
October 2013. Mahosot Hospital is a 350-bed government hospital in the Lao capital, Vientiane, which houses
a range of medical and surgical units. There were 21,549
people admitted to the hospital during 2013 and 3540
people admitted during the months of September and
October.
Routine testing of faeces in the Mahosot Hospital
Microbiology Laboratory consists of microscopy for white
cells, and culture for Salmonella and Shigella species only.
Vibrio species are sought using selective media (thiosulfatecitrate-bile salts-sucrose agar; TCBS agar) when indicated
by clinical or epidemiological features. The laboratory does
not routinely undertake any anaerobic culture or attempt
to detect Campylobacter species or viral enteric pathogens,
whilst microscopy for parasites is conducted in a separate
laboratory. Relatively small numbers of stool samples are
sent to the laboratory. However, because of concern that C.
difficile may be unrecognised in Laos, methods for C. difficile culture and identification were established as part of
routine stool examination for a 2 month period. Patients
gave oral consent for the collection of stool samples for
diagnosis of their illness.
A memo (in Lao language) was sent to the medical
teams in Mahosot Hospital notifying them of the introduction of C. difficile diagnostic techniques. The following
details were obtained for each specimen: date of specimen
collection, patient age and gender, clinical diagnosis as
listed on the test request form, the presence of stool white
cells on microscopy and the results of Salmonella/Shigella
culture. Other microbiologic details were noted if present;
e.g. the presence of faecal parasites on microscopy. Unfortunately it was not possible to obtain a reliable history for
prior antibiotic use for every patient.
Unformed faecal specimens were directly plated onto
half plates of selective differential medium (ChromID C.
difficile agar, bioMerieux, France) and streaked for single
colonies. Plates were incubated anaerobically (BD GasPak™
EZ Anaerobic Container System, Becton Dickinson, USA)
for 48 h before examination for colonies typical of C. difficile
(black, spreading, medusa-head colonies with a characteristic odour). Suspicious colonies were tested by latex agglutination according to the manufacturer’s instructions (Oxoid C.
difficile latex test kit, Oxoid, UK) to confirm their identity. A
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control strain of C. difficile (C. difficile ATCC 9689) was
used to validate test results. Isolates were stored at −80 °C
until shipment to Perth, Australia, for confirmation of
identity, testing for the presence of toxin genes (tcdA,
tcdB, and cdt) and ribotyping as described previously
targeting the 16S–23S rRNA gene using primers 5′CGTGGGGTGAAGTCGTAACAAGG-3′ (positions 1445
to 1466 of the 16S rRNA gene) and 5′-GCGCCCTT
TGTAGCTTGACC-3′ (positions 20 to 1 of the 23S rRNA
gene) [9]. Antimicrobial susceptibility testing was also
performed for moxifloxacin, metronidazole, clindamycin
and vancomycin using E-tests (Biomérieux, Marcy-l’Etoile,
France) with minimum inhibitory concentration (MIC)
results interpreted according to current US Clinical and
Laboratory Standards Institute (CLSI) guidelines.

Results
A total of 86 faecal samples were received during the
2 month period, 70 of which were available for C. difficile
culture. The median age was 35 years with a range of
240 days to 89 years. There were 31 females and 39 males.
Of the 70 patients included in the study, 26 were reported
to have diarrhoea, 14 had suspected typhoid fever, five had
fever of unknown etiology and two had suspected melioidosis. Salmonella spp. were isolated from six of the 70 samples and five were positive for C. difficile by culture and
latex agglutination. Three of the five isolates of C. difficile
were positive for the tcdB gene with two also tcdA positive
by polymerase chain reaction (PCR). There were five different RTs identified-RTs 014, 017, 020, QX 107 and QX 574,
with the latter two isolates being non-toxigenic (Table 1).
All isolates were susceptible to moxifloxacin, metronidazole
and vancomycin. Four of the five isolates were clindamycin
intermediate and isolate the RT QX107 isolate was clindamycin resistant with an MIC of 8 μg/ml.
Discussion
This is the first report, as far as we have been able to
establish, of the isolation of C. difficile from diarrheal
stool specimens in Laos. In a study of the etiology of
diarrhoea in Vientiane from 1996 to 1997, the presence
of C. difficile was not investigated [10], and there have
been no clinical reports of CDI in Laos, of which awareness amongst doctors appears low. However, increasing
awareness of this pathogen is leading to increased testing
and improved surveillance elsewhere in Asia [6]. It is
not possible to be certain that C. difficile was a primary pathogen in all five patients given the presence
of Salmonella sp. in two patients and the absence of
toxin genes in two of the C. difficile isolates. Furthermore,
two of the isolates were from 1-year-old children. C. difficile
is known to cause asymptomatic colonization in infants
under 2 years of age, so the C. difficile in these two cases
may not have been responsible for causing symptoms [11].
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Table 1 Clostridium difficile positive patients at Mahosot Hospital
Case

Age (Years)

Toxin gene profile

Ribotype

Stool culture

Clinical details

1

35

A-B-CDT-

QX 574

Negative

Family contact of S. typhi patient

Unknown

2

46

A + B + CDT-

UK 020

Salmonella sp.

Culture positive melioidosis, diarrhoea

Yes: ofloxacin 5 days

3

1

A-B + CDT-

UK 017

Salmonella sp.

Chronic diarrhoea

Yes: amoxicillin (unknown duration)
ceftriaxone 3 days

4

1

A-B-CDT-

QX 107

Negative

Diarrhoea, 4–5 days

Unknown

5

7

A + B + CDT-

UK 014

Negative

Diarrhoea, unknown duration

Unknown

Although many studies have been published on C.
difficile epidemiology worldwide, few are from Asia, and
in particular the Greater Mekong Subregion. Reports
from Thailand (Bangkok) predominate, with only a single report from Vietnam (Table 2). To date there are no
published data on C. difficile infection and epidemiology
from Laos, Cambodia or Myanmar showing the need for
further research in these countries. The incidence of C.
difficile infection in the different groups of patients listed
in Table 2 ranged from 6.5% to 44%. Different diagnostic
techniques were used for these studies, making comparisons difficult. Toxin enzyme immunoassay (EIA) tests
alone, as used in two of these studies [12, 13], have a lower
sensitivity compared to EIA paired with PCR [14, 15].
Three of the earliest Thailand studies also only looked at
toxin A or the tcdA gene [12, 13, 16]. Due to the high
regional prevalence of RT 017, which does not produce
toxin A, it is possible that the true incidence of CDI has
been underestimated in these studies [6].
All of the ribotypes detected in this current study have
been reported elsewhere. RTs 014 and 020 have been
isolated in several studies from Thailand and China and
were both isolated in this study [8, 17]. Due to the high
similarity of these two RTs, they are often reported in
studies as the ‘RT 014/020 group’. One RT 017 isolate
was identified in our study. This is a prevalent RT in
many countries in Asia and the predominant RT found
in Thailand, China and South Korea [8, 17, 18]. Two isolates of RT QX 107 were recently described for the first
time from Thailand [19] with our isolate being the third
detected in the region. This could suggest that this RT is
of Asian origin. The RT QX 574 isolated from this study
may also be unique to the region, as the only other
country the strain has been isolated from is Indonesia
(T. Riley, unpublished data). There were no hypervirulent RT 027 or RT 078 isolated from our small number
of patients. While both RT 027 and RT 078 have been
widely reported from Europe and North America [20–22],
there have only been sporadic reports from Asia, including
recent reports from mainland China [18, 23, 24]. The
spread of these RTs into mainland China could lead to further dissemination within South East Asia. RT 078 is more
commonly associated with community-acquired C. difficile
infection; hence hospital-based studies, as most of the

Prior antibiotic use

studies in this region have been, might miss cases caused
by this RT [25].
In Europe and the USA, the majority of C. difficile cases
are thought to result from person-to-person spread. Antimicrobial resistant bacteria have become an established
problem globally, and in particular in Asia, as a result of
widespread overuse and misuse of antibiotics [26, 27].
This is also important in the promotion of antibioticassociated diarrhoea and CDI. The use of clindamycin,
third generation cephalosporins, penicillins and fluoroquinolones greatly increases the risk of CDI [28], with the
third generation cephalosporins causing the highest attributable risk due to their frequent use in hospitals [29]. One
study showed that two thirds of patients with CDI had
received a cephalosporin during the two month period
before diagnosis [30]. The use of cephalosporins, particularly ceftriaxone, is increasing in Laos, with a 50% increase
in ceftriaxone usage seen in Mahosot Hospital since
2011 (Mahosot Hospital, unpublished data). Furthermore, nearly 50% of patients admitted to Mahosot Hospital
have evidence of having received antibiotics prior to admission [27]. This highlights the need for enhanced antimicrobial stewardship if further increases in CDI are to be
avoided.
Given the prevalence of factors which promote CDI,
and the evidence that CDI occurs at similar rates in Asia
as in other continents [6], we believe that CDI is likely
to be an under-recognised cause of diarrhoea in Laos
and adjoining countries. There are several reasons for
this under-diagnosis, including low clinician awareness
of CDI [31], limited access to diagnostic services, a disincentive to investigate diarrheal illnesses when the cost
of testing is borne by the individual, and short hospital
stays. These Lao results are limited by the small sample
size, the sparse clinical information available, and the
use of culture alone. However, we hope that this study
will alert clinicians and policy makers to the presence of
this bacterium in Laos. As in many parts of Asia, this
country is experiencing rapid economic and demographic changes, and changes in healthcare which will
further increase the potential importance of CDI. Enhanced surveillance will be required to fully appreciate
the extent and impact of CDI in Laos, and elsewhere in
the region.

Hospital patients (≥15 years)
Hospital patients with diarrhoea
>18 years

Hospital patients with diarrhoea

Bangkok, Thailand 47/175 (26.8%)

Bangkok, Thailand 105/422 (24.9%)

107/574 (18.6%)

45/479 (9.4%)

Thailand

Vietnam

Hospital patients with diarrhoea

Diarrheal inpatients (>14 years old) Immunochromatography (Remel
Xpect)

Bangkok, Thailand 25/203 (12.3%)

Toxin A EIA (Oxoid)

Luminex xTAG gastrointestinal
pathogen panel assay (Luminex
Molecular Diagnostics, Austin,
TX, USA)

EIA (Meridian Premier Cytoclone),
PCR

Cultured on C. difficile ChromID
agar (bioMérieux,
Marcy l’Etoile, France), in-house
PCRs for the presence
of tcdA and tcdB, and binary toxin
genes (cdtA and cdtB)

Toxin A/B by EIA (VIDAS;
bioMerieux), tcdB by PCR

Qualitative
immunochromatographic assay
(Xpect C. difficile toxin A/B test;
Thermo scientific,
Lenexa, KS, USA), 5-plex PCR and
an in-house PCR for the presence
of tcdA

HIV patients with diarrhoea

Cultured on cycloserine-cefoxitinfructose agar (CCFA, Oxoid) CD-D1
latex kit (Mitsubishi Chemical
Industries, Tokyo)

Patients with suspected
C. difficile infection

HIV-positive diarrheal patients,
HIV-positive non diarrheal
patients and HIV-negative
diarrheal patients

Bangkok, Thailand 140/472 (29.6%)
(20/34 HIV-positive diarrheal patients,
21/167 HIV-positive non-diarrheal
patients, 99/271 HIV-negative diarrhoeal
patients)

Culture on cycloserine-cefoxitinfructose agar, tcdA gene confirmed
by in- house PCR

Bangkok, Thailand 16/102 (15.6%)

Asymptomatic infants <12
months old, asymptomatic
children 1–11 years old,
antimicrobial treated diarrheal
adults, non-antimicrobial
treated diarrheal positive adults

Bangkok, Thailand 77/443 (17.4%)
(28/235 asymptomatic infants
16/76, asymptomatic children,
20/48 antimicrobial treated adults,
13/84 non-antimicrobial-treated adults)

Toxin A EIA (TechLab, BioWhittaker)

Tissue culture cytotoxin assay

Test method

Bangkok, Thailand 53

Antibiotic treated patients and
healthy controls. All >15 years

Bangkok, Thailand 21/320 (6.5%)
(15/140 clindamycin treated patients,
14/140 β-lactam-treated patients,
2/140 controls)

Clinical presentation

Patients with diarrhoea and
healthy controls. 84% of
patients infants aged 0–3 years

Number positive/number tested

Bangkok, Thailand 123/279 (44%)
(106/203 patients with diarrhoea
17/76 healthy controls)

Location, Country

Table 2 Clostridium difficile studies from the Greater Mekong Subregion

30 tcdA and 15 tcdB

48 tcdA and tcdB positive
by PCR

39 toxigenic- 27 tcdA,
12 tcdB

tcdB

tcdA, tcdB

tcdA, tcdB

20 tcdA positive (2 from
the infants and children
group, 10 from antimicrobial
treated adults and 8 from
non-antimicrobial treated
adults)

Gene

2010–2011

2008

2006–2008

1999–2000

Unknown
(published
2000)

1998–1999

1991–1994

1990

2009–2014

Unknown
(published
2003)

[36]

[35]

[19]

[14]

[34]

[17]

[13]

[33]

[16]

[12]

[32]

Year of study Reference

014/020 (17),
2015
010 (12), 017 (12),
039 (9), 009 (6)

UK 017 (23),
UK 014/020
(13), QX370 (1)

Ribotypes
(number
positive)
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Conclusions
With the isolation of C.difficile from human diarrhoeal
stool samples in Lao PDR, we can include this bacterium
as a potential diarrhoeal pathogen in this country. This
is an important first step in its recognition by clinicians
and epidemiologists both within the country itself and
the Greater Mekong Subregion of Asia. Future local
investment in the laboratory diagnosis of CDI, the typing
of isolates, and defining the clinical epidemiology of
infection in the region is required to better inform healthcare providers in the development of clinical management
algorithms, infection control and prevention practices,
and policies for the prudent use of antimicrobials.
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